🎉 M&A multiples are live!
Check it out!

Regulus Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Regulus Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Regulus Therapeutics Overview

About Regulus Therapeutics

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.


Founded

2009

HQ

United States of America
Employees

30

Website

regulusrx.com

Financials

LTM Revenue n/a

LTM EBITDA -$54.8M

EV

$51.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Regulus Therapeutics Financials

Regulus Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$54.8M.

In the most recent fiscal year, Regulus Therapeutics achieved revenue of n/a and an EBITDA of -$45.9M.

Regulus Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Regulus Therapeutics valuation multiples based on analyst estimates

Regulus Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$29.2M -$45.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$28.3M -$30.0M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Regulus Therapeutics Stock Performance

As of April 15, 2025, Regulus Therapeutics's stock price is $2.

Regulus Therapeutics has current market cap of $127M, and EV of $51.0M.

See Regulus Therapeutics trading valuation data

Regulus Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$51.0M $127M XXX XXX XXX XXX $-0.92

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Regulus Therapeutics Valuation Multiples

As of April 15, 2025, Regulus Therapeutics has market cap of $127M and EV of $51.0M.

Regulus Therapeutics's trades at n/a LTM EV/Revenue multiple, and -0.9x LTM EBITDA.

Analysts estimate Regulus Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Regulus Therapeutics and 10K+ public comps

Regulus Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $51.0M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.1x XXX XXX XXX
P/E -2.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Regulus Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Regulus Therapeutics Valuation Multiples

Regulus Therapeutics's NTM/LTM revenue growth is n/a

Regulus Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.7M for the same period.

Over next 12 months, Regulus Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Regulus Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Regulus Therapeutics and other 10K+ public comps

Regulus Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 57% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Regulus Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Regulus Therapeutics M&A and Investment Activity

Regulus Therapeutics acquired  XXX companies to date.

Last acquisition by Regulus Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Regulus Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Regulus Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Regulus Therapeutics

When was Regulus Therapeutics founded? Regulus Therapeutics was founded in 2009.
Where is Regulus Therapeutics headquartered? Regulus Therapeutics is headquartered in United States of America.
How many employees does Regulus Therapeutics have? As of today, Regulus Therapeutics has 30 employees.
Who is the CEO of Regulus Therapeutics? Regulus Therapeutics's CEO is Mr. Joseph P. Hagan.
Is Regulus Therapeutics publicy listed? Yes, Regulus Therapeutics is a public company listed on NAS.
What is the stock symbol of Regulus Therapeutics? Regulus Therapeutics trades under RGLS ticker.
When did Regulus Therapeutics go public? Regulus Therapeutics went public in 2012.
Who are competitors of Regulus Therapeutics? Similar companies to Regulus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Regulus Therapeutics? Regulus Therapeutics's current market cap is $127M
What is the current EBITDA of Regulus Therapeutics? Regulus Therapeutics's last 12-month EBITDA is -$54.8M.
What is the current EV/EBITDA multiple of Regulus Therapeutics? Current EBITDA multiple of Regulus Therapeutics is -0.9x.
Is Regulus Therapeutics profitable? Yes, Regulus Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.